In Brief: U.S. Surgical/Ethicon
This article was originally published in The Gray Sheet
U.S. Surgical/Ethicon: Dismissal by the federal court of appeals of Johnson & Johnson subsidiary Ethicon's trocar patent infringement claims against U.S. Surgical allows USSC to proceed to trial with its own patent infringement claims against Ethicon, the firm states in a Feb. 4 release. The appeals court dismissal affirms the earlier dismissal by the U.S. District Court in Hartford, Connecticut ("The Gray Sheet" Feb. 17, 1997, In Brief). The three patents in question involve all of the safety-shielded trocars manufactured by Ethicon since 1990. "Damages could exceed $500 mil. before trebling" if USSC prevails, the firm claims...
You may also be interested in...
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.